Reuters logo
BRIEF-FDA grants priority review for Lilly's abemaciclib
July 10, 2017 / 11:31 AM / 5 months ago

BRIEF-FDA grants priority review for Lilly's abemaciclib

July 10 (Reuters) - Eli Lilly And Co:

* FDA grants priority review for Lilly’s abemaciclib for the treatment of advanced breast cancer

* Eli Lilly And Co - ‍lilly intends to submit abemaciclib to European regulators in Q3 of 2017 and to Japanese regulators before end of 2017​

* Eli Lilly And Co - ‍working closely with fda and anticipates agency action on the application in Q1 of 2018 for abemaciclib​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below